



Q&A: Use the QA function (bottom center) to ask questions. Do not use the chat window to ask questions of the panelists.

Chat: Use the chat to engage with other attendees and alert the moderator to any technical issues.

Question didn't get answered? Send it to <u>memberservices@cogr.edu</u>.



This webinar is being recorded, and the recording will be made available in the COGR Portal Video Library.



Webinar slides are posted under meeting materials at <u>www.cogr.edu</u>.

Announcements



Going AI: Cutting-Edge Strategies for Enhancing Research Administration **Efficiency through Practical Application of Artificial Intelligence**

September 16, 2024

Speakers:



Daniel Harmon, Director of Data and Systems, Sponsored Programs Administration, University of Illinois at Urbana Champaign



Kirstin Morningstar, Executive Director of Regulatory Services, University of Texas at Arlington

Moderators:



Krystal Toups Director of Contracts & Grants Administration (COGR)





Karen Hartman, Vice Chair, Research Administration, Mayo Clinic



Lori Schultz, Senior Associate Vice President for Research, University of Texas at San Antonio



Kristin West **Director of Research Ethics** & Compliance (COGR)

TODAY'S AGENDA

- Al: Setting the Context
- Al and IRB Administration: A Use Case
- Enhancing research administration through automation and artificial intelligence
- Chatbots in Research Administration
- Q&A





Results from Registration Poll Questions



COGR Sept. 16, 2024, AI Webinar © All Rights Reserved 2024



<u>Question</u>: Is your institution currently using AI to assist in performing any research administration or research compliance tasks?



Total Number of Responders: 121

COGR Sept. 16, 2024, AI Webinar © All Rights Reserved 2024

Yes, 16% (N=19)

No, 55% (N=66)



Question: If your institution is using AI in performing research administration or research compliance tasks, what area(s) is it using it in? (Select all that apply).



COGR Sept. 16, 2024, AI Webinar © All Rights Reserved 2024

<u>Question</u>: If your institution is not yet using AI to assist in performing research administration or research compliance tasks, what has prevented you from doing so ? (Select all that apply).



taking the AI plunge.



Al: Setting the Context

IDEA > AWARD > CLOSEOUT LORI ANN M. SCHULTZ UTSA SEPT 2024

What is it anyway?

- AI/ML: Artificial "Intelligence" & Machine "Learning"
- NLP: Natural Language Processing
- LLM: Large Language Models
- ► GPT: Generative Pre-Training Transformer
- Prompt engineering







What does it look like on campus?

Critical Thinking: Do you want it to be fast? Or do you want it to be right?

🛆 Al Overview

Learn more

According to UC Berkeley geologists, people should eat **at least one small rock a day**. Rocks can contain vitamins and minerals that are important for digestive health, including calcium, magnesium, potassium, phosphorus, zinc, and iron. Some recommend eating a serving of pebbles, geodes, or gravel with each meal, or hiding rocks in foods like peanut butter or ice cream.

ResFrac Corporation : Geologists Recommend Eating At Least One Small Rock Per Day May 19, 2021	 The Geological Society The Geological Society Climate-Smart A Amendments Some of the vital mentality in modes in 	idi Ng ut
	All News Images Shopping Videos : More	has the US had? X I CONS
	 AI Overview The United States has had one Muslim preside 	Learn more : ent, Barack Hussein Obama.
	 Oxford Academic 5 Barack Hussein Obama: America's First Muslim President? Barack Hussein Obama: America's First Muslim President? Faith in the 	

Al Overview

Learn more

Cheese can slide off pizza for a number of reasons, including **too much sauce, too much cheese, or thickened sauce**. Here are some things you can try:

> ix in sauce: Mixing cheese into the sauce helps dd moisture to the cheese and dry out the sauce. ou can also add about 1/8 cup of non-toxic glue the sauce to give it more tackiness.

et the pizza cool: The cheese will settle and bond

The Research & Administration Lifecycle



Considerations



Data Management & Sharing / Public Access policies



Expectation of confidentiality

Peer review Business sensitive information



Regulated data: FERPA, HIPAA, Export Control, CUI, etc.

Faculty Scholarly Activity

Publications

Data Sets



Research Integrity Issues

Management Opportunities





Workload complexity scores

Data analysis

Policy creation

Development Opportunities & Challenges

Automation!

Visualization

Forecasting

the case for new positions



Informing workload analysis/benchmarking/making

Data governance & access at your institution

Talking Points for Leadership



AI does something we are not always good at: combining information in one place



But in world of vast amounts of public data, how are these broad collections viewed?



Understanding risks to information

Restricted (HIPAA, FERPA, CUI, Export Control. IRB, COI, etc) Business Sensitive information



Rather than view AI as a cost-cutting tool, whatCreated better jobs for your staffif it:Made better use of resources you already have?



AI and IRB Administration: AUse Case

Kirstin Morningstar

Executive Director of Regulatory Services



THE UNIVERSITY OF TEXAS AT ARLINGTON



COI Disclosure

I have no actual or potential conflict of interest in relation to this presentation.



Background – UTA's Institutional Review Board

- ~700 submissions per year
- •3 FTE Specialists + ¹/₂ FTE Coordinator
- •Electronic submission system "Mentis" (homegrown)
- Mix of biomedical and social/behavioral studies including clinical trials, Common Rule, and FDA regulated
- Conducts "flex reviews" for non-federally funded/non-FDA regulated protocols



How can we determine if AI is right for us? "Proof of concept" project – keep it small, expand later if successful

- Test on *internal* administrative process
- Partnered with Microsoft and Infused Innovations, December 2023
- Pulled in UTA IT personnel with understanding of research/IRB to handle technical components (developer access, technical implementation)
- Landed on idea to combine automation features with AI capabilities:







UTA IRB "Workflow"

- Tracking mechanism spreadsheet of pending submissions with protocol details, funding sources, regulatory coverage, review status, assigned reviewer
- Initial protocol entry made by Coordinator (5 10 minutes per entry, average 10 - 20 entries per day)
- Regulations (FDA, Common Rule) and Review Category (Exempt, Expedited, Full Board, Flex-MR, Flex-GMR) determined by Specialists during protocol review and entered into Workflow



UTA IRB "Workflow"





ueSheet	HSP Done?	COI Req'd?	Other Training Req'd? (GCP, RCR)	Assigned Reviewer	Current Study Status		Date of Last Action
	Yes			LA	Review	¥	2/27/2024
	yes			LA	Resubmission Waiting for Coordinator Review	¥	3/6/2024
	yes			SP	Waiting on Other Institution	÷	3/22/2024
	Yes	COI - yes	GCP- yes	SP	Resubmission Waiting for Coordinator Review	•	3/14/2024
	Yes			LA	Waiting for Initial IRB Coordinator Review	•	3/18/2024
	yes			SP	Waiting for Initial IRB Coordinator Review	÷	3/20/2024
					Sent to IRB		

Full Board Prep • 2024 CR tracking -**COVID** Research



Project Plan – Proof of Concept

- 1. Automation: automate entries into Workflow as protocols are submitted in electronic system
- 2. Al Decision-Making: combine data from electronic system + AI scan of protocol to predict applicable regulations and the review category (Exempt, Expedited, Full Board, Flex-MR, Flex-GMR)





Potential Benefits / Rationale

Automating Workflow Entries

- Eliminate dependency: entries maintained even if Coordinator is absent or position vacant
- Prevent bottleneck: entries made in real time, Specialists can act on them sooner

• Significant time savings: 10 – 20 submissions/day x 5 - 10 minutes/entry = 50 minutes to 3+ hours of time saved per day!!

- Efficiency: Specialists can selfassign based on expertise and time available
- Planning: earlier identification of potential Full Board items
- Accuracy: may reduce potential for human error
- Training: potential for use as training tool for new Specialists

Al Protocol Predictions



Development Process

- Provided specific sources and fields to pull data for Workflow auto entries
- Wrote rules/conditions for AI to predict review category
- EXAMPLE CONDITIONS (AI scans for funding source then makes predictions) based on these conditions):
- Regulations: FDA Only = Non-Federal Funded + "IRB Form: Devices in Human Subject Research" and/or "IRB Form: Drugs, Food, Dietary Supplements"
- Review Category: Full Board = If "Greater than Minimal Risk" is checked yes in #4 of Primary Research Application Form + Revised Common Rule, FDA, or Both FDA and Common Rule is the Regulation applied

Challenges from IRB Staff's Perspective

- Limited PoC scope 69% accuracy at handoff after three iterations
- Time-consuming translating IRB process for AI development team, writing conditions for AI predictions, testing/assessing multiple iterations, providing feedback after each iteration
- IT components beyond our (IRB) technical expertise
- Cost (both for development and monthly) luckily UTA has a high level of interest in leveraging innovative technology
- How to transition from test environment to real environment
- How to manage future "training" of AI to improve accuracy



How is it going?

- •Still early implemented late July 2024; tracking accuracy as we go
- •Glitches not recognizing resubmissions
- •Need more time to analyze its performance and impact
- Need help from our IT team or other partners for continued AI training/fine-tuning





Generated with AI: Adobe Firefly, 23 **April 2024**



AI Accuracy as of September 2024

Three fields: funding source, regulations applied, and review path prediction



All 3 Correct

2 Correct

1 Correct

0 Correct





Contact Kirstin Morningstar: kmorning@uta.edu

Generated with AI: Adobe Firefly, 3 April 2024

Feel free to reach out with any questions!!





ENHANCING RESEARCH ADMINISTRATION THROUGH AUTOMATION AND ARTIFICIAL INTELLIGENCE

Karen Hartman Vice Chair, Research Administration

COGR Webinar: Going Al September 16, 2024

Image copyright Shutterstock

Overview of Mayo Clinic Research

By the numbers:

- Over 5,000 personnel in research, inclusive of \bullet scientists, clinicians, allied health staff and post docs/fellows
- Annual Expenditures: **\$1.2B**
- Over **5,800** active clinical studies
- All study participant accruals of **116,000**
- Active animal studies of **1,250** \bullet

Research Administrative Services provided through several different offices and support structures



Basic Science









ROCHESTER **MINNESOTA**

JACKSONVILLE **FLORIDA**

PHOENIX & SCOTTSDALE ARIZONA



HEALTH SYSTEM MINNESOTA • IOWA • WISCONSIN

Automation Continuum



Adapted from: The Intelligent Automation Continuum, P. Gupta



ROBOTIC PROCESS AUTOMATION





ROBOTIC PROCESS AUTOMATION (RPA)

- Gathers info from various sources
- Follows pre-defines rules to complete tasks

 Used to automate repetitive, rule-based tasks

- Unable to think or learn
- Fragile changes will break them

Processes FDP Subawards

- Unattended BOT on scheduled cadence
- Accesses multiple systems
- Attaches Notice of Award (NOA) and Statement of Work (SOW) to subaward
- Saves the FDP template and uploads all documents to Contract Management System
- Tags as incomplete if anything is missing
- Triggers email to Contract Manager to review

MEET BEATRICE



C Contraxx		☆		Q (1 / 16	Θ	÷	112% 💌	₿.	Ţ ₽	l dr.	Ð 1	I Q
ashboard	¢													
Contracts	П			FDP Foreign Fixed Amount Subaward Run Template										
Villa V	M		Feder	al Awardir	ng Agency	: National Instit	tutes of Health	(NIH)			-			
ontracting Parties \sim	0		Pass-	Pass-Through Entity (PTE): Subrecipient:										
Vorkflow	8		Ma	Mayo Clinic ABC Test Company, Inc.										
lauses			PTE PI						Sub PI: Juli	ie A. Ha	anson			
Juories			PTE Fe	deral Awar	d No: 2R0	1NS076491-11			Subaward N	No: AB	C-306578; P	0#123456		
Reports 🗸			Subawa Start:	ard Buc	2	? End: 12/04	Go To Page	-	-	×	Action (USD):	\$ 0.00		
			Estima Start:	ed Period o 12/15/202	of Performan	ce: End: 11/30	Page: 4		of 16		ed Total (USD	D): \$0.0		
		•	1. 2.	PTE here budget fo independ incur any Party) sh behalf of PTE shal using Sul amount, s number s	by awards a r this Subaw ent entity an debts or ob all take any any other Pa any other Pa provide fun brecipient's s Subaward nu hall be retur	a fixed amount Su vard are as shown id not an employed ligations on behall action that attemp arty, without the a ding in accordance standard invoice, umber, and certified ned to Subrecipie	e or agent of l f of any other its or purports ffected party's ce with the Par but at a minim cation, as requ ent. Invoices a	K PTE. No Party, a to bind prior w yment S um sha ured in 2 nd ques	Cance o Party has to nd no Party any other Pa ritten approv chedule sho ll include the 2 CFR 200.4 tions concer	the author (includin arty in co val. own in At e delivera 115 (a). I ming inve), to Subrecipi award work, a prity to bind any og an employed ontract or to inc ttachment 5. Al able completed nvoices that do oice receipt or	ient. The Sta Subrecipient other Party or other rep or other rep ar any debt i invoices sh and milesto o not referen payments sh	tement of V shall be an in contract or obligation all be subm ne payment ce PTE Sub hall be direct	Vork and or to of such ns on itted t baward ted to



RESULTS

- Impact:

 - Prior manual effort (30 min) • Current - BOT run (4 min)
- Volumes:
 - 760 subawards processed
- 1 FTE savings (repurposed to higher level work)

Initiated Q1 2023

ARTIFICIAL INTELLIGENCE



THE CONTRACT NETWORK™

- Secure and neutral contract collaboration platform
- Utilizes market data and AI to speed up contract negotiation
- Uses generative AI to align unfamiliar agreements with site internal standards and market benchmarks
- Minimizes time spent on negotiations & tracking status

My Clinical Trial Agreement Receipt Report Summary of changes



- The record retention period for study records has been reduced from two years to one year after marketing authorization or discontinuation of research on the study drug.
- The sponsor's termination notice period has been extended from thirty days to sixty days.
- The review period for publications has been reduced from sixty days to thirty days.

Disclosure: Mayo Clinic has equity in TCN

Agreements

ATR-307989	(Fix-It Test) ···				
AGREEMENT TYPE	MY PARTY COUNTERPARTY	STATUS % COMPLETE			
Clinical Trial Agreement (C Party Counterparty	DRAFT 0%			
File View Summary	y Signature 💽 Show inline markup	A Manage access Send to counterparty			
a Agreement for Draft on Augus 1. Overview 2. Pro	analysis	a, & Inventions 4. Confidential Information 5. Audits & Inspections 6. Public			
Q Search profil	es				
PRESENCE 🗘	TOPIC 0	SUMMARY 🗘			
NO	Alternative Dispute Resolution	The agreement does not mention or address alternative dispute resolution m			
YES	Agreement Term	Term of the Agreement is for the duration of the Study, may be extended or te Certain obligations survive beyond termination.			
NO	CRO	The agreement does not mention or involve a Clinical Research Organization			
YES	Effective Date	The agreement becomes effective on the date of last signature.			
YES	Agreement Name	Name of the Agreement: CLINICAL TRIAL AGREEMENT.			
NO	Insurance	The agreement does not address the issue of insurance.			



ATR-307989 (Fix-It Test)

AGREEMENT TYPE Clinical Trial Agreement (CTA)	MY PARTY COUNTERPA	ARTY STATUS	% COMPLETE
File View Summary Sign	ature 💽 Show inline m	arkup 🕺 Manage acc	ccess 🛛 🔊 Send to counterparty 🔍 🏎 Sign r

My Party edits
 Counterparty edits
 Variables

a) Publishable Results.

 (\mathbf{i})

i. Research Institution reserves the right for it and the Principal Investigator to publish and/orand present the Study Data and Results and any information relating thereto ("Proposed Manuscripts") in accordance with this Section 7.1. Before publishing or presenting, however, Research Institution, through Principal Investigator, agrees to submit copies of any and all Proposed Manuscripts to Sponsor at least thirty (30) days in advance of submitting such Proposed Manuscripts to a publisher or other third party. Research Institution and Principal Investigator understand that this requirement acknowledges Sponsor's responsibility to evaluate such Proposed Manuscripts: (i) for accuracy and consonance with Sponsor's database as stipulated by FDA regulations; (ii) to ascertain whether Confidential Information is being inappropriately utilized and/or released; (iii) to provide Research Institution and Principal Investigator with information which may not yet be available to them; and (iv) to provide input from other investigators and subinvestigators in the Study, if any, regarding the content and conclusions of the Proposed Manuscripts. Research Institution will consider Sponsor's comments but is not obligated to incorporate them. If Sponsor makes a good faith determination within such thirty (30)-day period that the publication or presentation of such Proposed Manuscript would be detrimental to its or its affiliates' intellectual property interests, upon Sponsor's written notification, Research Institution and Principal Investigator shall refrain from submitting such Proposed Manuscript to a publisher or other third party for up to an additional ninety (90) sixty (60) days to allow Sponsor or its affiliates to file patent applications or take other steps to protect its or its affiliates' intellectual property interests. Research Institution agrees to and will require Principal Investigator to removes all Confidential Information from such Proposed Manuscript upon Sponsor's written request.



ii. The foregoing notwithstanding, Research Institution and Principal Investigator acknowledge that this is a multi-center study, and that Sponsor has an interest in ensuring that a multi-center publication is the first publication to be released or presented regarding the Study. Research Institution agrees that it shall not, and will require that Principal Investigator agree that he/she/they will not, independently publish or present any Study Data or Results until the sooner of (a) such a multi-center publication is released; (b) the Sponsor confirms in writing that there will not be a multi-center publication; or (c) the elapse of eighteen (18) months following the completion or termination of the Study. The multi-center





IN PROGRESS...

- **Automation Opportunities** • Dept of Educ (Sect 117) reporting Committee member scheduling • Find research staff

- **AI Opportunities**
- Protocol ingest
- Digital schedule of activities (events)



Karen Hartman hartman.karen@mayo.edu Karen Hartman | LinkedIn

Tara Rabe Rabe.tara@mayo.edu Tara Rabe | LinkedIn

THANKS FOR YOUR TIME

©2024 Mayo Foundation for Medical Education and Research | slide-44

Chatbots in Research Administration

Director of Data and Systems, Sponsored Programs Administration



DanielHarmon

UNIVERSITY OF ILLINOIS RBANA-CHAMPAIGN







INTRODUCTION TO AI-POWERED CHATBOTS

VV Ty_l F

- What are chatbots
- Types of chatbots
 - Rule-based vs.Al-Powered
- Historical Connotations

AI IS IMPROVING FAST



November 2022

Credit: Ethan Mollick – One Useful Thing



August 2024

BENEFITS OF AI-POWERED CHATBOTS IN RESEARCH ADMINISTRATION

- 24/7 Availability
- Frees up staff time
- Automation of repetitive tasks
- Consistent and friendly voice
 - There are no dumb questions!
- Data collection and insights



GENERATION)



Image Source: https://neo4j.com/developer-blog/knowledge-graph-rag-application/

TOOLS

Vector Database

- Azure Al Search
- Pinecone
- Faiss
- Chroma
- Elasticsearch

LLMs

- OpenAl GPT (3.5,4, 4 Turbo, 4o) Azure Al Studio
- Llama (open source)
- Anthropic Claude 3 (Haiku, Sonnet, Opus)
- Google Gemini
- Mistral
- Microsoft Phi-3
- Hugging Face

Tooling

- Copilot Studio
- Amazon Lex
- Google Vertex Al
- Limitless options from vendors utilizing these tools

WHAT IS IT GOING TO COST ME ?!

IMPLEMENTATION STRATEGY



×I ×I	Nee
	Sele
	Inte
	Trai
	Test

eds and goals assessment

ecting the right AI technology

egration with Existing Systems

ining and Customization

ting and Deployment

CHALLENGES AND CONSIDERATIONS

- Technical Challenges (integration, maintenance)
- Data Privacy and security concerns
- Hallucinations
- Bias



DEMOSAND WHAT WE LEARNED



Thank you!

